DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer

Clinical trial NCT04509596 · COMPLETED

Trial details

NCT number: NCT04509596
Sponsor: Dizal Pharmaceuticals
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Breast Cancer Metastatic

Start date: 2020-09-21
Primary completion: 2022-07-07
Enrollment: 23

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.